Infertility Pregnancy and Childbirth Infertility
Conditions
Interventions
Controlled ovarian hyperstimulation and in-vitro fertilisation. Two groups of poor responders going through IVF (200 in each group).
Intervention: 75 mg DHEA daily
Cont
Sponsors
Homerton University Hospital NHS Foundation Trust (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 24/10/2017: Inclusion criteria are based on the ESHRE definition of poor responders and would include any patient with any two of the following: 1. Age = 40 years 2. Markers for poor ovarian reserve (AMH 40 years 2. Markers for poor ovarian reserve [Anti-Mullerian Hormone (AMH) 15 IU, Antral Follicle Counts (AFC) < 6] 3. Previous poor response to ovarian stimulation (less than three mature follicles on day of hCG trigger/cycle cancellation due to poor response/less than three oocytes retrieved)
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 24/10/2017: 1. Women ?42 years 2. Women with premature ovarian failure/premature menopause (FSH>40 U/L) 3. Women already taking DHEA. 4. Patients with a known allergy to the trial drug or any of the active ingredients in the placebo Previous exclusion criteria: 1. Women > 42 years 2. Women with premature ovarian failure/premature menopause (FSH > 40 U/L)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rates (ultrasound confirmation of a foetus with a heartbeat at 6-8 weeks gestation) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Ovarian reserve defined AMH levels before and after ten weeks of DHEA supplementation 2. Number of eggs retrieved 3. Number and quality (grade) of embryos available for transfer/freezing 4. Ongoing pregnancies after 14 weeks gestation (miscarriage rates) | — |
Countries
England, Scotland, United Kingdom
Outcome results
None listed